Sanofi logo

Sanofi

SNY

NASDAQHealthcareDrug Manufacturers - General

Previous close

$45.85

+$0.70 · +1.55%

Aug 21, 4:00 PM ET

SNY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

79

Undervalued

Momentum

38

Weakening

Sentiment

62

Bullish

Risk resilience

74

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
FR
CEO
Belén Garijo López
Listed since
Jul 1, 2002
Employees
76,493

Market position

Day range

Current $45.85

52-week range

Current $45.85

Open
$45.31
Previous close
$45.15
Volume
1.86M
0.58× average
Average volume
3.19M
Average daily volume
Market cap
110.1B USD
Beta
0.28
Market reference 1
50-day average
$43.4948
+5.41% above average
200-day average
$46.0343
-0.40% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
113.34B EUR
P/E (TTM)
24.14×
P/B (TTM)
1.36×
P/S (TTM)
1.94×
EV / EBITDA
9.08×
Earnings yield
7.76%
Free cash flow yield
10.08%
Dividend yield
5.22%

Profitability & efficiency

Gross margin
72.77%
Operating margin
20.58%
Net margin
8.09%
Return on equity
10.95%
Return on assets
6.16%
Return on invested capital
7.70%

Financial health

Debt / equity
0.34×
Current ratio
1.09×
Altman Z-score
1.55
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends78%54%30%7%Gross margin, FY2021: 68.72%Gross margin, FY2022: 70.71%Gross margin, FY2023: 69.66%Gross margin, FY2024: 70.18%Gross margin, FY2025: 72.07%Operating margin, FY2021: 20.74%Operating margin, FY2022: 25.05%Operating margin, FY2023: 16.72%Operating margin, FY2024: 16.38%Operating margin, FY2025: 20.54%Net margin, FY2021: 15.89%Net margin, FY2022: 20.64%Net margin, FY2023: 12.98%Net margin, FY2024: 12.55%Net margin, FY2025: 16.72%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.72%. Gross margin FY2022 70.71%. Gross margin FY2023 69.66%. Gross margin FY2024 70.18%. Gross margin FY2025 72.07%. Operating margin FY2021 20.74%. Operating margin FY2022 25.05%. Operating margin FY2023 16.72%. Operating margin FY2024 16.38%. Operating margin FY2025 20.54%. Net margin FY2021 15.89%. Net margin FY2022 20.64%. Net margin FY2023 12.98%. Net margin FY2024 12.55%. Net margin FY2025 16.72%.

Income trends

Revenue

46.72B EUR+5.49%

Operating income

9.6B EUR+32.34%

Net income

7.81B EUR+40.52%
Income trends across reported periods50.85B EUR34.32B EUR17.79B EUR1.27B EURRevenue, FY2021: 39.18B EURRevenue, FY2022: 40.56B EURRevenue, FY2023: 41.62B EURRevenue, FY2024: 44.29B EURRevenue, FY2025: 46.72B EUROperating income, FY2021: 8.13B EUROperating income, FY2022: 10.16B EUROperating income, FY2023: 6.96B EUROperating income, FY2024: 7.25B EUROperating income, FY2025: 9.6B EURNet income, FY2021: 6.22B EURNet income, FY2022: 8.37B EURNet income, FY2023: 5.4B EURNet income, FY2024: 5.56B EURNet income, FY2025: 7.81B EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 39.18B EUR. Revenue FY2022 40.56B EUR. Revenue FY2023 41.62B EUR. Revenue FY2024 44.29B EUR. Revenue FY2025 46.72B EUR. Operating income FY2021 8.13B EUR. Operating income FY2022 10.16B EUR. Operating income FY2023 6.96B EUR. Operating income FY2024 7.25B EUR. Operating income FY2025 9.6B EUR. Net income FY2021 6.22B EUR. Net income FY2022 8.37B EUR. Net income FY2023 5.4B EUR. Net income FY2024 5.56B EUR. Net income FY2025 7.81B EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue46.72B EUR44.29B EUR41.62B EUR40.56B EUR39.18B EUR
Cost of goods sold13.05B EUR13.21B EUR12.63B EUR11.88B EUR12.26B EUR
Gross profit33.67B EUR31.08B EUR28.99B EUR28.68B EUR26.92B EUR
Research and development7.84B EUR7.39B EUR6.51B EUR6.5B EUR5.69B EUR
Selling, general, and administrative10.24B EUR9.18B EUR8.93B EUR8.74B EUR9.56B EUR
Operating expenses24.07B EUR23.83B EUR22.03B EUR18.52B EUR18.79B EUR
Interest income331M EUR457.53M EUR530.5M EUR168.96M EUR3.13M EUR
Interest expense626M EUR622.58M EUR512.82M EUR384.8M EUR377.37M EUR
Depreciation and amortization5.68B EUR3.59B EUR4.43B EUR3.11B EUR3.35B EUR
Operating income9.6B EUR7.25B EUR6.96B EUR10.16B EUR8.13B EUR
Net income7.81B EUR5.56B EUR5.4B EUR8.37B EUR6.22B EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+4.10%
11 comparable reports
Latest EPS result
1.21
Estimate 1.1 · Beat by 10.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.791.41.010.62Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 0.7, estimate 0.71, surprise -1.41%, Miss. Q2 2025, reported Apr 24, 2025: actual 0.94, estimate 0.9, surprise +4.44%, Beat. Q3 2025, reported Jul 31, 2025: actual 0.9, estimate 0.96, surprise -6.25%, Miss. Q4 2025, reported Oct 24, 2025: actual 1.7, estimate 1.6, surprise +6.25%, Beat. Q1 2026, reported Jan 29, 2026: actual 0.89, estimate 0.84, surprise +5.95%, Beat. Q2 2026, reported Apr 23, 2026: actual 1.1, estimate 1.06, surprise +3.77%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.21, estimate 1.1, surprise +10.00%, Beat. Q4 2026, reported Oct 23, 2026: actual —, estimate 1.71, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates16.04B13.12B10.2B7.28BQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 30, 2025: actual 7.9B USD, estimate 9.51B USD, surprise -16.89%, Miss. Q2 2025, reported Apr 24, 2025: actual 11.63B USD, estimate 10B USD, surprise +16.31%, Beat. Q3 2025, reported Jul 31, 2025: actual 12.64B USD, estimate 12.36B USD, surprise +2.28%, Beat. Q4 2025, reported Oct 24, 2025: actual 15.43B USD, estimate 11.11B USD, surprise +38.89%, Beat. Q1 2026, reported Jan 29, 2026: actual 14.34B USD, estimate 11.71B USD, surprise +22.38%, Beat. Q2 2026, reported Apr 23, 2026: actual 12.94B USD, estimate 12.68B USD, surprise +2.09%, Beat. Q3 2026, reported Jul 30, 2026: actual 14.06B USD, estimate 13.02B USD, surprise +7.99%, Beat. Q4 2026, reported Oct 23, 2026: actual —, estimate 15.18B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$49.50

7.96% upside
Past 12 months12-month forecastHigh $50.00Average $49.50Low $49.00

Rating distribution

27 ratings
Strong buy00%
Buy1244%
Hold1452%
Sell14%
Strong sell00%

Recent analyst actions

9 institutions
Exane BNP ParibasdowngradeOutperformNeutral
B of A SecuritiesdowngradeBuyNeutral
UBSdowngradeBuyNeutral
BarclaysdowngradeOverweightEqual Weight
GuggenheimdowngradeBuyNeutral

SNY news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$2.1953

2025 complete year+15.2% since 2021

2026 partial: $2.419

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend May 4, 2026

$2.419

Annual

Record May 4, 2026 · Payment Jun 3, 2026

Dividend

Ex-dividend May 9, 2025

$2.1953

Annual

Record May 9, 2025 · Payment Jun 12, 2025

Dividend

Ex-dividend May 9, 2024

$2.0369

Annual

Record May 10, 2024 · Payment Jun 6, 2024

Dividend

Ex-dividend May 30, 2023

$1.903

Annual

Record May 31, 2023 · Payment Jun 23, 2023

Dividend

Ex-dividend May 26, 2022

$0.297

Special

Record May 27, 2022 · Payment Jun 27, 2022

Dividend

Ex-dividend May 4, 2022

$1.747

Annual

Record May 5, 2022 · Payment May 31, 2022

SNY peers

ETFs holding SNY

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SNY

research.disclaimer